XenoPort Plans To Sell 10 Mln Shares In Underwritten Public Offering

(RTTNews) - XenoPort Inc. (XNPT), a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders, announced that it intends to offer and sell 10.00 million shares of its common stock in an underwritten public offering.

XenoPort also intends to grant the underwriters a 30-day option to purchase up to a maximum of 1.50 million additional shares of common stock. All of the shares in the proposed public offering are to be sold by XenoPort.

Credit Suisse Securities (USA) LLC is acting as sole book-running manager for the offering. RBC Capital Markets, LLC and Wells Fargo Securities, LLC are acting as co-managers.